Breakpoints

home_filledExplore shows

listSubscriptions

playlist_addQueue

addAdd by RSS Feed

Settings

Help Content policies Publisher guidelines

Send feedback

open_in_newGet the Android app open_in_newGet the iOS app

Privacy · Terms

Breakpoints

Society of Infectious Diseases Pharmacists

Subscribe

Visit website

The SIDP Podcast

Breakpoints

Available episodes



Newest first

Oldest first

#74 – Breakpoints Talks Breakpoints: Piperacillin/tazobactam

Episode Notes Drs. Jim Lewis, Mike Satlin (@MSatlin) and Jason Pogue (@jpogue1) are back with Dr. Erin McCreary (@ErinMcCreary) for episode two of a five-episode miniseries all about breakpoints! Join our panelists as they discuss breakpoint updates on piperacillin/tazobactam. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/ Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#73 – You’re a Breakpoint, Harry: Magical Insights from CLSI and USCAST

Episode Notes Drs. Jim Lewis, Mike Satlin (@MSatlin) and Jason Pogue (@jpogue1) join Dr. Erin McCreary (@ErinMcCreary) for episode one of a five-episode miniseries all about breakpoints! Over the next five weeks, our panelists will cover breakpoint updates on piperacillin/tazobactam, aminoglycosides, fluoroquinolones, and non-fermenters. You won’t want to miss this series! Our first episode will tackle questions related to breakpoints themselves – a seemingly mystical art! How does a breakpoint become a breakpoint? How often are breakpoints updated? How do we implement all of these recent breakpoint changes into clinical practice? Tune in for answers to these questions and more! Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/ Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#72 – This Isn't Just a Phage: A Discussion on Bacteriophage Therapy

Episode Notes Drs. Saima Aslam (@DocSaimaAslam) and Daria Van Tyne (@DariaVanTyne) join Dr. Rachel Britt (@RachelBPharmD) for a discussion on bacteriophage therapy! Tune in for a review of their role in therapy, logistical considerations, the future of phage therapy, and more! Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/ Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#71 – This is a Potential Breakup Song: Controversies in the Management of Infective Endocarditis

Episode Notes Episode Notes Inspired by lamentations on Twitter, Drs. Bobbi Jo Stoner (@BobbiJo_Stoner), Jonathan Ryder (@JonathanRyderMD) and Sami El-Dalati join Dr. Jillian Hayes (@thejillianhayes) to hash out some of the controversies we encounter while managing infective endocarditis. Do we really need gentamicin and rifampin for all cases of staphylococcal prosthetic valve endocarditis? Where do oral antimicrobials fit into this disease state? Who should have a seat at the table to provide the most comprehensive care to these patients? Tune in for the answers to these questions and more! Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/ References: IDSA/AHA Infective Endocarditis Guidelines: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000296 Deconstructing the Dogma: Systematic Literature Review and Meta-analysis of Adjunctive Gentamicin and Rifampin in Staphylococcal Prosthetic Valve Endocarditis: https://pubmed.ncbi.nlm.nih.gov/36408468/ Twitter Poll – Gabe Vilchez (March 2021): https://twitter.com/IdVilchez/status/1372148761112240131?s=20&t=fYuyNWGmzZACWrpUb7Fp3g Survey of ID Physicians on Gent and Rifampin Use: https://pubmed.ncbi.nlm.nih.gov/32964063/ Bacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis: https://academic.oup.com/jac/article/52/5/820/760105 Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus: https://journals.asm.org/doi/abs/10.1128/AAC.34.12.2312 Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations: https://journals.asm.org/doi/abs/10.1128/aac.35.12.2611 Rifampin Combination Therapy for Nonmycobacterial Infections: https://journals.asm.org/doi/10.1128/CMR.00034-09 ARREST Trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32456-X/fulltext Is Rifampin Use Associated With Better Outcome in Staphylococcal Prosthetic Valve Endocarditis? A Multicenter Retrospective Study: https://pubmed.ncbi.nlm.nih.gov/32706879/ Nephrotoxicity of vancomycin, alone and with an aminoglycoside: https://pubmed.ncbi.nlm.nih.gov/2351627/ Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia: https://journals.asm.org/doi/10.1128/AAC.02483-18 Multicenter Cohort of Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments: https://academic.oup.com/ofid/article/7/1/ofz538/5691187 CERT Trial (in process): https://clinicaltrials.gov/ct2/show/NCT04886284 Rifampin for Surgically Treated Staphylococcal Infective Endocarditis: A Propensity Score-Adjusted Cohort Study: https://pubmed.ncbi.nlm.nih.gov/26872729/ A step-by-step guide to implementing a multidisciplinary endocarditis team: https://journals.sagepub.com/doi/10.1177/20499361211065596 Management of Infective Endocarditis in People Who Inject Drugs: A Scientific Statement from the American Heart Association: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001090?cookieSet=1 Infectious Complications of Addiction: A Call for a New Subspecialty Within Infectious Diseases: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319263/ A Cross-sectional Analysis of Linezolid in Combination with Methadone or Buprenorphine as a Cause of Serotonin Toxicity: https://academic.oup.com/ofid/article/9/7/ofac331/6625822 POET Trial: https://www.nejm.org/doi/full/10.1056/nejmoa1808312 Risk of New Bloodstream Infections and Mortality Among People Who Inject Drugs With Infective Endocarditis: https://pubmed.ncbi.nlm.nih.gov/32785635/ Comparing right- and left sided injection-drug related infective endocarditis: https://pubmed.ncbi.nlm.nih.gov/33441950/ Evaluation of Partial Oral Antibiotic Treatment for Persons Who Inject Drugs and Are Hospitalized With Invasive Infections: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745005/ Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna: https://pubmed.ncbi.nlm.nih.gov/29659732/ Impact of the duration of antibiotic therapy on relapse and survival following surgery for active infective endocarditis: https://academic.oup.com/ejcts/article/55/4/760/5126415 Bacteriological Outcome after Valve Surgery for Active Infective Endocarditis: Implications for Duration of Treatment after Surgery: https://academic.oup.com/cid/article/41/2/187/529954 Long-term Risk of Hemorrhagic Stroke in Patients With Infective Endocarditis: A Danish Nationwide Cohort Study: https://academic.oup.com/cid/article/68/4/668/5039147 Sign of the Times: Updating Infective Endocarditis Diagnostic Criteria to Recognize Enterococcus faecalis as a Typical Endocarditis Bacterium: https://pubmed.ncbi.nlm.nih.gov/35262664/ Prevalence of colorectal disease in Enterococcus faecalis infective endocarditis: results of an observational multicenter study: https://pubmed.ncbi.nlm.nih.gov/31444092/ Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#70 – Stewardship Struggles

Episode Notes Drs. Valerie Vaughn (@ValerieVaughnMD), Jason Newland (@JasonGNewland) and Libby Dodds Ashley (@The_Real_LDA) join Dr. Erin McCreary (@ErinMcCreary) for a discussion on how to harness the power of data to move through those common stewie struggles. Tune in for a review of common barriers, the art of communication within stewardship, and more! This podcast is sponsored by bioMérieux. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

#69 – IDWeek 2022 Recap: Practice Changing Publications – Midnights Edition

Episode Notes Your Breakpoints hosts, Drs. Erin McCreary (@ErinMcCreary), Julie Ann Justo (@julie_justo), Rachel Britt (@RachelBPharmD) and Jillian Hayes (@thejillianhayes) are back for a second week of IDWeek review. Tune in for publications that may change your practice, and a segment of I Feel Nerdy that is sure to Swiftly become one of your favorites! Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ References: Bacterial: _ GRACE-VAP: https://pubmed.ncbi.nlm.nih.gov/35394515/ Follow-up Blood Cultures: https://pubmed.ncbi.nlm.nih.gov/36136334/ SABATO: https://clinicaltrials.gov/ct2/show/NCT01792804 ZeNix: https://pubmed.ncbi.nlm.nih.gov/36053506/ SHINE: https://pubmed.ncbi.nlm.nih.gov/35263517/ _Viral: MYR301: doi: 10.1016/j.dld.2022.01.047, https://www.natap.org/2021/EASL/EASL_14.htm STOMP: https://clinicaltrials.gov/ct2/show/NCT05534984 MINMON: https://pubmed.ncbi.nlm.nih.gov/35026142/ ANCHOR: https://pubmed.ncbi.nlm.nih.gov/35704479/ HPTN083: https://pubmed.ncbi.nlm.nih.gov/34379922/ HPTN084: https://pubmed.ncbi.nlm.nih.gov/35378077/ ATLAS-2M: https://pubmed.ncbi.nlm.nih.gov/34648734/ LAI-ART in an Urban HIV Clinic: https://pubmed.ncbi.nlm.nih.gov/35913500/ Fungal: CandiSep: https://pubmed.ncbi.nlm.nih.gov/35708758/ 1,3 BDG and GM as Diagnostic Tools: https://pubmed.ncbi.nlm.nih.gov/34173659/ Single-Dose Ampho for Crypto: Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis - PubMed (nih.gov) Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/ Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#68 – IDWeek 2022 Recap: Late Breaking Trials and Pipeline Antibacterials

Episode Notes Missing IDWeek already? Hoping for some new content to consume during your holiday travel plans? Have no fear – your IDWeek Breakpoints recap is here! Join your Breakpoints hosts, Drs. Erin McCreary (@ErinMcCreary), Julie Ann Justo (@julie_justo), Rachel Britt (@RachelBPharmD) and Jillian Hayes (@thejillianhayes) for a review of some new trials and pipeline agents presented at IDWeek 2022. Be sure to stay tuned for Part II, launching next Friday! Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/ Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#67 – Nixing the Nidus: Managing Retained Sources in Prosthetic Joint Infections

Dr. Laura Certain (@laura_certain) and Dr. Nico Cortes-Penfield (@Cortes_Penfield) join Dr. Julie Ann Justo (@julie_justo) to discuss all things related to prosthetic joint infections. Tune in to learn about what comprises a bacterial biofilm, how it develops, and ways to combat it using the latest evidence-based antibiotic regimens. We also take a look at what’s on the horizon for the field of orthopedic infectious diseases. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ References: * Cortés-Penfield NW, Kulkarni PA. The History of Antibiotic Treatment of Osteomyelitis. Open Forum Infect Dis. 2019 Apr 8;6(5):ofz181. doi: 10.1093/ofid/ofz181. PMID: 31123692. * Bernard L, et al. Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection. N Engl J Med. 2021 May 27;384(21):1991-2001. doi: 10.1056/NEJMoa2020198. PMID: 34042388. (DATIPO trial) * Gallagher C, et al. Impact of Implementing an IV to PO Antibiotic Treatment Protocol for Orthopedic Infections ion Prescribing Habits and Health Utilization Outcomes. IDWeek 2022. Poster 909. * Febrile Podcast. Episode #31 – Truth or DAIR. 2022 Feb 28. https://febrilepodcast.com/episode-31-truth-or-dair/ * Frank JM, et al. The Mark Coventry, MD, Award: Oral Antibiotics Reduce Reinfection After Two-Stage Exchange: A Multicenter, Randomized Controlled Trial. Clin Orthop Relat Res. 2017 Jan;475(1):56-61. doi: 10.1007/s11999-016-4890-4. PMID: 27387759. * Kelly MP, et al. Extended Oral Antibiotics Increase Bacterial Resistance in Patients Who Fail 2-Stage Exchange for Periprosthetic Joint Infection. J Arthroplasty. 2022 Aug;37(8S):S989-S996. doi: 10.1016/j.arth.2022.01.027. PMID: 35074446. * Payne J, et al. Inducing Antimicrobial Resistance with Long-term Antibiotics at Stage 2 Revision for Periprosthetic Joint Infection. IDWeek 2022. Poster 981. * Frost P, et al. Phototoxic potential of minocycline and doxycycline. Arch Dermatol. 1972 May;105(5):681-3. PMID: 5026677. * Lode H, et al. Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000. Antimicrob Agents Chemother. 1979 Jul;16(1):1-6. doi: 10.1128/AAC.16.1.1. PMID: 475366. * Sader HS, et al. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers. Diagn Microbiol Infect Dis. 1993 Aug-Sep;17(2):143-50. doi: 10.1016/0732-8893(93)90025-3. PMID: 8243035. * Green S & Tsai YV. Precision Dosing of To-Marrow: Linezolid Therapeutic Drug Monitoring. ContagionLive: Bench to Bedside with SIDP. 2022 Nov 3. https://www.contagionlive.com/view/precision-dosing-of-to-marrow-linezolid-therapeutic-drug-monitoring Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints. Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#66 – The Swinging PEN-dulum: Evolving Approaches to Cephalosporin Use in Penicillin Allergic Patients

Dr. Kimberly Blumenthal (@KimberlyBlumen1), Dr. Meghan Jeffres (@PharmerMeg), and Dr. Eric Macy (@EricMacyMD) join Dr. Julie Ann Justo (@julie_justo) to summarize the history of cephalosporin avoidance in penicillin allergies, evidence-based pros and cons of giving cephalosporins in penicillin allergy, how to leverage technology to improve treatment of patients with penicillin allergies, and much more! Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ References * Macy E. Why Was There Ever a Warning Not to Use Cephalosporins in the Setting of a Penicillin "Allergy"? J Allergy Clin Immunol Pract. 2021 Nov;9(11):3929-3933. doi: 10.1016/j.jaip.2021.06.059. PMID: 34303019. * Liang EH, et al. Adverse Reactions Associated with Penicillins, Carbapenems, Monobactams, and Clindamycin: A Retrospective Population-based Study. J Allergy Clin Immunol Pract. 2020 Apr;8(4):1302-1313.e2. doi: 10.1016/j.jaip.2019.11.035. PMID: 31821919. * Macy E, Contreras R. Adverse reactions associated with oral and parenteral use of cephalosporins: A retrospective population-based analysis. J Allergy Clin Immunol. 2015 Mar;135(3):745-52.e5. doi: 10.1016/j.jaci.2014.07.062. PMID: 25262461. * Macy E, et al. Population-Based Incidence of New Ampicillin, Cephalexin, Cefaclor, and Sulfonamide Antibiotic "Allergies" in Exposed Individuals with and without Preexisting Ampicillin, Cephalexin, or Cefaclor "Allergies". J Allergy Clin Immunol Pract. 2022 Feb;10(2):550-555. doi: 10.1016/j.jaip.2021.10.043. PMID: 34757066. * Picard M, et al. Cross-Reactivity to Cephalosporins and Carbapenems in Penicillin-Allergic Patients: Two Systematic Reviews and Meta-Analyses. J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2722-2738.e5. doi: 10.1016/j.jaip.2019.05.038. PMID: 31170539. * Romano A, et al. Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell-mediated hypersensitivity to penicillins. J Allergy Clin Immunol. 2016 Jul;138(1):179-186. doi: 10.1016/j.jaci.2016.01.025. PMID: 27016799. * Romano A, et al. Cross-Reactivity and Tolerability of Cephalosporins in Patients with IgE-Mediated Hypersensitivity to Penicillins. J Allergy Clin Immunol Pract. 2018 Sep-Oct;6(5):1662-1672. doi: 10.1016/j.jaip.2018.01.020. PMID: 29408440. * Blumenthal KG, et al. The Impact of a Reported Penicillin Allergy on Surgical Site Infection Risk. Clin Infect Dis. 2018 Jan 18;66(3):329-336. doi: 10.1093/cid/cix794. PMID: 29361015. * Blumenthal KG, et al. Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study. BMJ. 2018 Jun 27;361:k2400. doi: 10.1136/bmj.k2400. PMID: 29950489. * Blumenthal KG, et al. Recorded Penicillin Allergy and Risk of Mortality: a Population-Based Matched Cohort Study. J Gen Intern Med. 2019 Sep;34(9):1685-1687. doi: 10.1007/s11606-019-04991-y. PMID: 31011962. * Macy E, Contreras R. Health care use and serious infection prevalence associated with penicillin "allergy" in hospitalized patients: A cohort study. J Allergy Clin Immunol. 2014 Mar;133(3):790-6. doi: 10.1016/j.jaci.2013.09.021. PMID: 24188976. * AAAI. Choosing Wisely. 2014 Mar 3. https://www.choosingwisely.org/clinician-lists/american-academy-allergy-asthma-immunlogy-non-beta-lactam-antibiotics-penicillin-allergy/ * Jeffres MN, et al. Systematic review of professional liability when prescribing β-lactams for patients with a known penicillin allergy. Ann Allergy Asthma Immunol. 2018 Nov;121(5):530-536. doi: 10.1016/j.anai.2018.03.010. PMID: 29551402. * Macy E, et al. Association Between Removal of a Warning Against Cephalosporin Use in Patients With Penicillin Allergy and Antibiotic Prescribing. JAMA Netw Open. 2021 Apr 1;4(4):e218367. doi: 10.1001/jamanetworkopen.2021.8367. PMID: 33914051. * Blumenthal KG, et al. Addressing Inpatient Beta-Lactam Allergies: A Multihospital Implementation. J Allergy Clin Immunol Pract. 2017 May-Jun;5(3):616-625.e7. doi: 10.1016/j.jaip.2017.02.019. PMID: 28483315. * Jeffres M. Penicillin and/or Beta-Lactam Allergy Tip Sheet & Cross-reactivity Table. https://drive.google.com/file/d/1cokYXnSDlO3vk8ke1LaalPz4iavuNSV8/view?usp=share_link * Khan DA, et al. Drug allergy: A 2022 practice parameter update. J Allergy Clin Immunol. 2022 Sep 17:S0091-6749(22)01186-1. doi: 10.1016/j.jaci.2022.08.028. Epub ahead of print. PMID: 36122788. * Guyer AC, et al. Allergy Electronic Health Record Documentation: A 2022 Work Group Report of the AAAAI Adverse Reactions to Drugs, Biologicals, and Latex Committee. J Allergy Clin Immunol Pract. 2022 Nov;10(11):2854-2867. doi: 10.1016/j.jaip.2022.08.020. PMID: 36151034. * Iammatteo M, et al. Safety and Outcomes of Oral Graded Challenges to Amoxicillin without Prior Skin Testing. J Allergy Clin Immunol Pract. 2019 Jan;7(1):236-243. doi: 10.1016/j.jaip.2018.05.008. PMID: 29802906. * Bavbek S, et al. Determinants of nocebo effect during oral drug provocation tests. Allergol Immunopathol (Madr). 2015 Jul-Aug;43(4):339-45. doi: 10.1016/j.aller.2014.04.008. PMID: 25088674. * DePestel DD, et al. Cephalosporin use in treatment of patients with penicillin allergies. J Am Pharm Assoc (2003). 2008 Jul-Aug;48(4):530-40. doi: 10.1331/JAPhA.2008.07006. PMID: 18653431. Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints. Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#65 – Into the Unknown: Exploring Fever of Unknown Origin with Febrile Podcast

In this special collaborative episode, Dr. Sara Dong (@swinndong) of Febrile podcast (@febrilepodcast) and Dr. Ghady Haidar (@cleverwebber) join Dr. Erin McCreary (@ErinMcCreary) to discuss all aspects of FUO, including classification, diagnosis, management, and more! Have the fever of unknown origin review article from the February 2022 edition of NEJM (@NEJM) handy to follow along with the group. References Haidar G, Singh N. Fever of unknown origin. N Engl J Med 2022;386:463-77. LinkedIn: https://www.linkedin.com/company/sidp/ Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#64 – Putting the Fun in Fungi: A Fun-guide to New Antifungals

In this spore-tacular episode of Breakpoints, Drs. Nathan Wiederhold and Kayla Stover (@stoverkr) join Dr. Erin McCreary (@ErinMcCreary) to discuss updates on the antifungal pipeline, offer pearls regarding their place in therapy, and teach us how to pronounce the drug names. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ References * Hoenigl M, Sprute R, Egger M, et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs. 2021;81(15):1703-29. Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#63 – I Never Metapneumovirus that Required Antibiotics: Prevention & Treatment of Common Respiratory Viruses in Adults

Episode Notes Drs. Ann Falsey, Crystal Hodge (@Howzzeee) and Michael Ison (@MichaelGIsonMD) join Dr. Jillian Hayes (@thejillianhayes) for a review of non-COVID respiratory viruses. Tune in for a review of current epidemiological changes, the vaccine pipeline, and current treatment options. This episode was supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp References * Community-acquired respiratory viruses in transplant patients (PMID 31511250) * Clinical Transplantation 2019 special issue on Transplant Infectious Diseases Guidelines: ](https://urldefense.com/v3/https:/onlinelibrary.wiley.com/toc/13990012/2019/33/9;!!OToaGQ!ujpO69U-82gjgidcyi6YshodQ4u…

#62 – Novel TheraPOOtics: The Microbiome, C. difficile, and LBPs

In this spore-tacular episode of Breakpoints, Drs. Anne Gonzales-Luna (@anniejayTX) and Paul Feuerstadt (@DrPaulGastro) join Dr. Rachel Britt (@rachelbpharmd) to discuss the microbiome, its relationship to C. difficile, and the new area of microbiota-based live biotherapeutic products (LBPs). This podcast was sponsored by an unrestricted medical education grant from Ferring Pharmaceuticals. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#61 – Dosing Consult: Linezolid Therapeutic Drug Monitoring

In the second episode of Breakpoints' Dosing Consult series, Drs. Ryan Crass (@crasspofungin) and Amit Pai (@DosingMatters) join Dr. Jillian Hayes (@thejillianhayes) to break down the 5 Ws and 1 H of linezolid TDM. LinkedIn: https://www.linkedin.com/company/sidp/ Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx Bibliography * Abdul-Aziz MH, et al. Intensive Care Med. 2020 Jun;46(6):1127-1153. doi: 10.1007/s00134-020-06050-1. Epub 2020 May 7. PMID: 32383061. * Abdul-Aziz MH, et al. Ther Drug Monit. 2022 Feb 1;44(1):19-31. doi: 10.1097/FTD.0000000000000940. PMID: 34750338. * Andes D, et al. Antimicrob Agents Chemother. 2002;46(11):3484-3489. doi:10.1128/AAC.46.11.3484-3489.2002. PMID: 12384354. * Bandín-Vilar E, et al. Clin Pharmacokinet. 2022;61(6):789-817. doi:10.1007/s40262-022-01125-2.…

#60 – Going MAD for Non-COVID ID Literature: A Year in Review LIVE from MAD-ID

In this special LIVE podcast episode, Drs. Emily Heil (@emilylheil) and Erin McCreary (@Erin McCreary) sit down at MAD-ID 2022 (@MAD_ID_ASP) and give a rundown of 36 of some of the best ID papers, abstracts, studies, and other cool stuff from 2021 and early 2022! They cover everything from ECCMID late breakers to gram-negative RCTs to stewardship to fungi (but NOT COVID-19). Listen now! Handout: https://drive.google.com/file/d/1OdYP9WpNGFmslw_G_vTPYF0cJZoxN8jo/view LinkedIn: https://www.linkedin.com/company/sidp/ Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx References PMIDs * IMPRESU: 34620666 * TARGET: 35106617 * MERINO-2: 34395716 * Tazobactam SIDP Insight: 34689349 * TMP-SMX vs FQ for Steno: 35097154 * Elexacaftor-Tezacaftor-Ivacaftor: 35142340 * Antibiotic Inertia: 34596206…

#59 – Resistance in Pseudomonas aeruginosa: Pearls and Perils

Drs. Antonio Oliver (@aoliverp73) and Maggie Monogue (@MaggieMonogue) join Dr. Erin McCreary (@Erin McCreary) to discuss all things Pseudomonas aeruginosa. Tune in to learn from some of the best about the complexities of P. aeruginosa resistance, the role of various antibiotics in the management of DTR isolates, and much more! This podcast was sponsored by an unrestricted medical education grant from Abbvie. LinkedIn: https://www.linkedin.com/company/sidp/ Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx References Shields RK, et al. Clin Infect Dis. 2022;ciac097. doi: 10.1093/cid/ciac097. Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#58 – We're Gonorrhea-valuate: Updates and Implementation of STI Treatment Guidelines

Drs. Brian Werth (@bdubrx), Zack Nelson (@zacroBID) and Amy Brotherton (@AmyBrother10) join Dr. Jillian Hayes (@thejillianhayes) to discuss updates in the management of sexually transmitted infections. Listen in for guidance on how doses are selected, practical implementation of guideline changes, and how to discuss these changes with patients. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ References * St. Cyr S, et al. Update to CDC’s Treatment Guidelines for Gonococcal Infection, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1911–1916. doi: http://dx.doi.org/10.15585/mmwr.mm6950a6. * STI treatment guidelines. Centers for Disease Control and Prevention. https://www.cdc.gov/std/treatment-guidelines/default.htm. Published 2021. Accessed May 12,…

#57 – Dosing Consult: Ceftriaxone

Drs. Tom Dilworth and Stephanie Shealy May (@stephshealymay) join Dr. Rachel Britt (@RachelBPharmD) in the first episode of Breakpoints Dosing Consults to discuss questions and debates around ceftriaxone dosing. When should we use 1g over 2g? How does critical illness affect what dose to use? Is ceftriaxone the most approachable antibiotic? Tune in for answers to these questions and more! Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ References * Ettestad PJ, Campbell GL, Welbel SF, Genese CA, Spitalny KC, Marchetti CM, Dennis DT. Biliary complications in the treatment of unsubstantiated Lyme disease. J Infect Dis. 1995 Feb;171(2):356-61. doi: 10.1093/infdis/171.2.356. PMID: 7844372. * Hasegawa S, Sada R, Yaegashi M, Morimoto K, Mori T; Adul…

#56 – Empiric Escalation: Gazing into the Crystal Ball for Multidrug-Resistant Gram-Negatives

Drs. Kate DeSear (@IDPharmD_Kate) and Frank Tverdek (@FTverdek) join Dr. Julie Ann Justo (@julie_justo) to discuss the practice of empiric escalation in this episode of our gram-negative resistance series. Listen in for encouragement on following your intuition and tips on how, when, and why to practice this other side of antimicrobial stewardship. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ References * Clinical and Laboratory Standards Institute. Access Our Free Resources: M100 and M60. Accessed at https://clsi.org/standards/products/free-resources/access-our-free-resources/ * Gallagher JC, et al. Open Forum Infect Dis. 2018 Oct 31;5(11):ofy280. doi: 10.1093/ofid/ofy280. PMID: 30488041. * Castan B, et al. Infect Dis Now. 2021 Sep;51(6)…

#55 – One World: Global Perspectives in Antimicrobial Stewardship

Drs. Debbie Goff (@idpharmd), Khalid Eljaaly (@khalideljaaly), and Angeliki Messina (@AngPharmID) join Dr. David Ha (@DHpharmd) as part of a global panel discussion on international antimicrobial stewardship practices. Listen in to learn about pharmacy practice in South Africa and Saudi Arabia, antimicrobial stewardship practices in these and other countries, and how you too can get involved in global stewardship. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ References * 2022 ACCP Global Conference on Clinical Pharmacy. https://www.accp.com/meetings/abstracts.aspx * Alhazzani W, Alshahrani M, Alshamsi F, Aljuhani O, Eljaaly K, Hashim S, et al. The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Ther…

#54 – Connecting with our Colleagues: COVID-19 Treatments in Community Pharmacies

Dr. Jennifer Morrow joins Dr. Rachel Britt (@RachelBPharmD) on this bonus episode of the Breakpoints podcast to discuss how the introduction of COVID-19 therapeutics and vaccines has affected community pharmacy teams and workflows. Also mentioned are the recent Test to Treat initiative, impacts on future community pharmacy practice, and ways inpatient providers can help our community colleagues. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ References: * https://aspr.hhs.gov/TestToTreat/Documents/Fact-Sheet.pdf * Torres, N. S., Abercrombie, J. J., Srinivasan, A., Lopez-Ribot, J. L., Ramasubramanian, A. K., & Leung, K. P. (2016). Screening a commercial library of pharmacologically active small molecules against staphylococcus aureus biofilms.…

#53 – Abscessus and fortuitum and avium, Oh My!: Updates and Controversies in NTM Management

Drs. Wendi Drummond and Jeff Pearson (@jeffpears0n) join Dr. Rachel Britt (@RachelBPharmD) on the Breakpoints podcast this week to discuss all things on non-tuberculosis mycobacteria pulmonary infections. Listen for answers to all your burning questions like “Are we still using IV amikacin?” and “How do I get omadacycline for my patient?” as well as learning why clofazimine is the coolest drug out there. For more NTM content, check out Dr. Drummond’s podcast, NTMTalk! This podcast was sponsored by an unrestricted medical education grant from Paratek. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ References: * www.doi.org/10.1093/cid/ciaa241 * www.doi.org/10.1164/rccm.200604-571ST * www.doi.org/10.1136/thoraxjnl-2015-207360 * w…

#52 – A Conversation with the Authors of IDSA Guidance on Treatment of AmpC, CRAB, and Stenotrophomonas

Drs. Pranita Tamma (@pranita_tamma) and Sam Aitken (@OncIDPharmd) are BACK on the podcast this week with Dr. Erin McCreary (@ErinMcCreary) to discuss IDSA guidance on AmpC producers, carbapenem-resistant Acinetobacter baumanii, and Stenotrophomonas as part of our series on gram-negative bacteria. Listen as the panelists navigate the hot mess that is the CRAB treatment landscape, have a minocycline appreciation moment (we stan for Steno Sam!), and throw down some bar trivia in an "I Feel Nerdy" segment that you don't want to miss. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ References * Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant E…

#51 – A Conversation with the Authors of IDSA Guidance on Treatment of ESBL, CRE, and DTR Pseudomonas

Drs. Pranita Tamma (@pranita_tamma) and Sam Aitken (@OncIDPharmd), authors of the IDSA Guidance on gram-negative resistance, join Dr. Erin McCreary (@ErinMcCreary) for this exquisitely good episode to discuss the soon-to-be-updated guidance on treatment of ESBL producers, CRE producers, and difficult to treat (DTR) Pseudomonas. Learn more about the Society of Infectious Diseases Pharmacists: * Website: https://sidp.org/About * Twitter: @SIDPharm (https://twitter.com/SIDPharm) * Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) * Facebook: https://www.facebook.com/sidprx * LinkedIn: https://www.linkedin.com/company/sidp/ References: * PRO: Testing for ESBL production is necessary for ceftriaxone-non-susceptible Enterobacterales: perfect should not be the enemy of progress - PubMed (nih.gov) * CON: Testing for ESBL production is unnecessary for ceftriaxone-resistant Enterobacterales - PubMed (nih.gov) * Infectious Diseases Society of America Guidance on the T…

#50 – Moving to the Algo-rhythm of IDWeek 2021: Highlights in SoMe and ASP

Episode Notes Drs. Timothy Gauthier (@IDstewardship) and Jillian Hayes (@thejillianhayes) join Dr. Zahra Kassamali Escobar (@zkePharmD) to recap some IDWeek 2021 highlights on social media and antimicrobial stewardship. The views and opinions expressed in this podcast are that of the speakers and do not necessarily reflect those of any past, current, or potential future employer. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ References: * Vosoughi S et al. The spread of true and false news online. Science 2018;359:1146-1151. doi: 10.1126/science.aap9559. * Solis Arce JS et al. COVID-19 vaccine acceptance and hesitancy in low-and middle-income countries. Nature Medicine 2021;27:1385-1394. doi: 10.1038/s41591-021-01454-y. * Metlay JP et al…

#49 – A PGY-What Now? A Primer on ID Pharmacy Fellowships

Episode Notes Drs. Keith Rodvold and Taylor Morrisette (@TayMorrisette) join Dr. Julie Ann Justo (@julie_justo) to discuss ID pharmacy fellowships, their pros and cons compared to other post-graduate training opportunities, the ID "pharmily tree," and Mai Tais. Find more information on ID pharmacy fellowships available in the United States here: -SIDP Fellowship Listings -ACCP Directory of Residencies, Fellowships, and Graduate Training Programs Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#48 – Aligning Goals: Antibiotics in End of Life Care

Drs. Molly Sinert and Jon Furuno join Dr. David Ha (@DHpharmd) to discuss the prevalence of antibiotic use and its harms and benefits in reducing suffering and providing comfort during end-of-life care. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ References: * Sinert et al. Guidance for Safe and Appropriate Use of Antibiotics in Hospice Using a Collaborative Decision Support Tool. Accessed October 6, 2021. https://oce-ovid-com.laneproxy.stanford.edu/article/00129191-202008000-00005/HTMLA * Albrecht JS, McGregor JC, Fromme EK, Bearden DT, Furuno JP. A Nationwide Analysis of Antibiotic Use in Hospice Care in the Final Week of Life. Journal of Pain and Symptom Management. 2013;46(4):483-490. doi:10.1016/j.jpainsymman.2012.09.010 * Furuno JP…

#47 – A Nefarious Orchestra: Gram-Negative Resistance Mechanisms Part 2

From generating 150 liters-worth of E. coli to the first X-ray crystallography of an ESBL, Drs. Robert Bonomo, Ryan Shields (@ryankshields), and Erin McCreary (@ErinMcCreary) take a deep dive into beta-lactamases like AmpCs, KPCs, and more.

#46 – A Nefarious Orchestra: Gram-Negative Resistance Mechanisms Part 1

Mechanisms of antibiotic resistance help us understand and recognize antibiotic susceptibility patterns that don't make sense. Robert Bonomo and Ryan Shields (@ryankshields) join Erin McCreary (@ErinMcCreary) to discuss efflux and porin mechanisms of resistance in Gram negative bacteria and their impact on antibacterial treatment. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#45 – Expectation vs. Reality: An Insider look at the OVERCOME and MERINO-2 trials

Pathogen-directed trials are among the most important trials that clinicians need to guide therapy but are also incredibly difficult to design and enroll. Rachel Britt (@RachelBPharmD) gets a behind-the-scenes interview with Adam Stewart (@adm_stewart), lead investigator of MERINO-2, and Jason Pogue (@jpogue1), lead investigator of OVERCOME. They discuss original intentions and evolving expectations to investigate optimal antibiotic therapy for multidrug resistant bacteria. Listen in for the insider analysis! Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#44 – The VaxScene, a review of the COVID-19 vaccine landscape in the US with a focus on equitable distribution and vaccine hesitancy

Jacinda Abdul-Mutakabbir (@jayCdoesID) and Jeannette Bouchard (@jlbouchard001) join Erin McCreary (@ErinMcCreary) to discuss COVID vaccines, including access to, confidence in, and hesitancy around them. This episode was sponsored by an unrestricted educational grant from Janssen Therapeutics, Division of Janssen Products, LP References: * Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383:2603-2615. * Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;384:403-416. * Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med 2021 * Rosenblum HG, Hadler SC, Moulia D, et al. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Imm…

#43 – Level Up: Implementation of Beta-lactam Therapeutic Drug Monitoring

Erin McCreary (@erinmccreary) reviews clinical data and implementation strategies for therapeutic drug monitoring of beta-lactam antibiotics with Veena Venugopalan (@Veena_PharmD), Joseph Kuti, Jason Roberts (@jasonroberts_pk), and Marc Scheetz (@IDPharmacometrx). Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#42 – The Level is in the Details: Beta-lactam Therapeutic Drug Monitoring

Erin McCreary (@erinmccreary) discusses clinical rationale behind therapeutic drug monitoring of beta-lactam antibiotics with Veena Venugopalan (@Veena_PharmD), Joseph Kuti, Jason Roberts (@jasonroberts_pk), and Marc Scheetz (IDPharmacometrx). For BCIDP credit, visit https://sidp.org/BCIDP References: * https://pubmed.ncbi.nlm.nih.gov/32383061/ 2. https://clicktime.symantec.com/3BcGw6g11AZY2rSUu7KpT1D7Vc?u=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F34136822%2F3. https://pubmed.ncbi.nlm.nih.gov/33480024/ * https://pubmed.ncbi.nlm.nih.gov/32910809/ Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#41 – The Gray Zone: Antimicrobial Stewardship in Immunocompromised Hosts

Promoting evidence-based antimicrobial stewardship for patients with immunocompromising conditions can be tricky when they’re often excluded from clinical studies. Dr. Zahra Kassamali Escobar (@ZKEPharmD) explores this gray zone with Dr. Catherine Liu and Dr. Justine Ross (@abella_ross) References: Fluoroquinolone Prophylaxis * Bucaneve et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353:977-87. DOI: 10.1056/NEJMoa044097 * Cullen et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353:988-98. DOI: 10.1056/NEJMoa050078 * Drayson et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicenter, double-blind, placebo-controlled, randomized, phase 3 trial. Lancet Oncology 2019; 20(12):1760-72. DOI: 10.1016/S1470-2045(19)30506-6 * Satlin et al. Colonization with fluoroquinolone-resistant enterobacterales decreases the effectiveness of…

#40 – Breakpoints Talks Breakpoints: Microbiology Labs and Stewardship

In this episode, host Dr. Erin McCreary (@erinmccreary) talks all things micro labs and stewardship with Dr. Romney Humphries (@romneyinla), Dr. Mary Hutton (@m3rkat), and Dr. Joseph Lutgring. From cascading results and breakpoint changes, to making connections within and outside of the lab, we hope you listen, laugh, and learn! > Show notes: * Mary’s paper: Microbiology Comment Nudge Improves Pneumonia Prescribing - PubMed (nih.gov) * CDC Key Activities and Roles for Microbiology Lab Staff in Antibiotic Stewardship Programs: Key Activities and Roles for Microbiology Laboratory Staff in Antibiotic Stewardship Programs Updated: August 2020 (cdc.gov) * CDC Selective Reporting: Selective Reporting of Antimicrobial Susceptibility Testing Results: A Primer for Antibiotic Stewardship Programs (cdc.gov) * CLSI M100 * EUCAST Breakpoints: EUCAST: Clinical breakpoints and dosing of antibiotics * USCAST Breakpoints: Breakpoints - USCAST

#39 – A Little More on the Littles: What Adults Should Know about ID Pediatrics

In this rapidfire episode Dr. Erin Weslander (@littlebugdrug), Dr. Laura Bio (@StanfordPedsASP), and Dr. Diana Yu (@dyupharmd) reveal their super-secret ID toolkit to figure out dosing and approaches to treatment in pediatric patients. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#38 – You're KID-ding! Myths in ID Pediatrics

Dr. Erin Weslander (@littlebugdrug), Dr. Laura Bio (@StanfordPedsASP), and Dr. Diana Yu (@dyupharmd) breakdown common myths about antimicrobials in pediatric patients. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#37 – A Gab about Cab: The Short on Long-Acting Antiretrovirals for HIV

Dr. Fidelia Bernice, Dr. Rodrigo Burgos, and Dr. Neha Pandit, join Breakpoints to discuss the first available long-acting antiretroviral agent, cabotegravir/rilpivirine. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#36 – Monoclonal Antibodies: Gateway Drugs for Future Care Delivery Models

Dr. Susan Davis (@IDPharmProf), Dr. Emily Spivak (@EmilySpivak), and Dr. Minkey Wungwattana (@minkeyw) join Dr. Erin McCreary (@ErinMcCreary) to discuss individual and shared experiences operationalizing COVID-19 monoclonal antibody therapy across their institutions and states. They tackle big and small hurdles from finding ways to ensure equitable distribution to pronouncing the drug names! This episode was sponsored by an unrestricted grant from Regeneron Pharmaceuticals. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#35 – Oral Beta-Lactams, Are We Serious?

Dr. Jill Cowper (@jillcowper), and Dr. Jesse Sutton, join host Dr. Zahra Kassamali Escobar (@zkePharmD) to discuss the data behind use of oral beta-lactams as step-down therapy for bacteremia and other serious infections. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ References: * Sutton J, Stevens V, Chang NN et al. Oral β-Lactam Antibiotics vs Fluoroquinolones or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Enterobacterales Bacteremia From a Urine Source. JAMA Netw Open. 2020 Oct 1;3(10):e2020166. * Punjabi C, Tien V, Meng C, et al. Oral Fluoroquinolone or Trimethoprim-Sulfamethoxazole vs ß-Lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis, Open Forum Infect Dis 2019; 6(10):o…

#34 – The New Scoop on Poop: Updates in the Management of C. difficile infections

Dr. Kevin Garey (@GareyKgarey), Dr. Kelly Reveles (@KellyReveles), Dr. Mandelin Cooper, and host Dr. Rachel Britt (@RachelBPharmD) discuss proposed updates of the IDSA-SHEA C. difficile guidelines, including: fidaxomicin over oral vancomycin as first-line therapy, the roles and logistical hurdles of fecal microbiota transplant, bezlotoxumab, and the pros and cons of prophylaxis. Timestamps 1:16 - Panel introductions 3:19 - Fidaxomicin vs PO vancomycin for first occurrence 7:21 - Fidaxomicin cost effectiveness 11:26 - Factors to consider for health systems when considering switch to fidaxomicin 14:23 - Fidaxomicin vs PO vancomycin for recurrences 17:52 - Role of pulsed and tapered PO vancomycin 19:57 - Role of fecal microbiota transplant (FMT) 22:24 - Challenges of FMT and where pharmacy fits in 27:27 - Bezlotoxumab 31:54 - Feasibility issues with bezlotoxumab and strategies to address them 35:25 - CDI prophylaxis 40:28 - Stewardship's role in reducing C. difficile infections Referen…

#33 – A Lung Time Coming: Controversies in Community Acquired Pneumonia

Join Dr. Elizabeth Covington (@ewood_1875), Dr. Brandon Dionne (@BWDionne), Dr. Jason Pogue (@jpogue1), and Dr. David Ha (@DHpharmd) as they discuss new and old antibiotic therapies for community acquired pneumonia, just how typical are atypicals, what happened to HCAP, and much more! This episode was sponsored by an unrestricted educational grant from Paratek Pharmaceuticals Time stamps: 00:00 Intro, guest bios 03:54 Procalcitonin 10:06 Pneumococcal and legionella antigen testing 16:30 Outpatient CAP therapy 23:40 Newer agents 31:18 Inpatient CAP therapy 39:09 Atypical coverage for admitted patients 44:27 Beta-lactam combination therapy 46:58 Ceftaroline vs ceftriaxone for pneumococcal pneumonia 55:23 Steroid use in CAP Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linked…

#32 – Unsolicited Advice: An Honest Discussion of Burnout in Stewardship

Join Dr. Julie Szymczak @julieszymczak, Dr. Emily Heil @emilylheil, Dr. Zahra Kassamali Escobar @zkepharmd, and Dr. Erin McCreary @erinmccreary, for a discussion on stewardship burnout—what is it, who is at risk for it, and what can we do about it? Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#31 – “Mind the Gap”: Antimicrobial Stewardship at Transitions of Care

Antimicrobial stewardship is often an inpatient effort and overlooked at transitions of care. Dr. April Dyer (@aprildyerid) and Dr. Rachel Kenney (@rkenneypharmd) share insight with host Dr. David Ha (@DHpharmD) on current practice and barriers, and strategies for pharmacists to bring antimicrobial stewardship in the discharge process. Episode content: * 00:14: Welcome and introductions: * 04:39: Project overview: "Developing Patient Safety Outcome Measures and Measurement Tools for Antimicrobial Stewardship Program” * 06:45: Scope of the problem (Scarpato et al.) * 07:56: Michigan data (Vaughn et al.) * 09:13: Building a business case * 12:32: Where to Start? * 12:54: Henry Ford Health System experience * 15:18: IT solutions * 17:22: 1% rule * 20:26: Identifying and engaging key players * 20:47: Outpatient pharmacy * 22:29: Skilled nursing facilities * 23:19: Case management relationship * 24:23: Barriers to implementation * 29:08: Quantifying total d…

#30 – Is More Better? The Role of Combination Therapy for MRSA

Host Erin McCreary (@erinmccreary) and expert panelists Dr. Katie Barber (@IDKatieBarb), Dr. Warren Rose (@Warren_E_Rose), and Dr. Steven Tong (@syctong) discuss data from early laboratory work to randomized, clinical trials for various antibiotic combinations used in the treatment of MRSA bacteremia. This was our most requested topic to cover on Breakpoints, and we hope you enjoy! Please complete this brief survey to help us continue to improve Breakpoints content: https://docs.google.com/forms/d/e/1FAIpQLSeriW-TAgiBik2_gdJllCZ4WqADhUyFIZtTAgYAYxRU5YU3hA/viewform?vc=0&c=0&w=1&flr=0 Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#29 – What You May Have Missed Due to COVID-19: ID Literature Updates 2020 Part 2

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) discuss notable infectious diseases publications from the first half of 2020. Papers discussed: 1) Van Duin D, et al. Lancet Infect Dis. 2020 Jun;20(6):731-741. doi: 10.1016/S1473-3099(19)30755-8. 2) Livermore DM, et al. Clin Infect Dis. 2020 Feb 6;ciaa122. doi: 10.1093/cid/ciaa122. 3) Falcone M, et al. Clin Infect Dis. 2020 May 19;ciaa586. doi: 10.1093/cid/ciaa586. 4) Lodise TP, et al. J Antimicrob Chemother. 2020 May 28;dkaa197. doi: 10.1093/jac/dkaa197. 5) O’Donnell JN, et al. Clin Ther. 2020 Jul 16;S0149-2918(20)30315-5. doi: 10.1016/j.clinthera.2020.06.005. 6) Abdul-Aziz MH, et al. Intensive Care Med. 2020 Jun;46(6):1127-1153. doi: 10.1007/s00134-020-06050-1. 7) Cusumano JA, et al. Am J Health Syst Pharm. 2020 Jul 7;77(14):1104-1112. doi: 10.1093/ajhp/zxaa128. 8) Roberts JA, et al. Clin Infect Dis. 2020 Mar 9;ciaa224. doi: 10.1093/cid/ciaa224. 9) Ackerman A, et al. Antimicrob Agents Chemother. 2020 May 21;64(6):e00…

#28 – What You May Have Missed Due to COVID-19: ID Literature Updates 2020 Part 1

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) discuss notable infectious diseases publications from the first half of 2020! Papers discussed: 1) Rybak MJ, et al. Am J Health Syst Pharm. 2020 May 19;77(11):835-864. doi: 10.1093/ajhp/zxaa036. 2) Scheetz MH. Am J Health Syst Pharm. 2020 May 19;77(11):810-811. doi: 10.1093/ajhp/zxaa076. 3) Alosaimy S, et al. Clin Infect Dis. 2020 July 27;ciaa1039. doi: 10.1093/cid/ciaa1039. 4) Rhee C, et al. Clin Infect Dis. 2020 May 6;ciaa059. doi: 10.1093/cid/ciaa059. 5) Heil EL, et al. Pharmacotherapy. 2020 Apr;40(4):368-371. doi: 10.1002/phar.2384. 6) Townsend SR, et al. Clin Infect Dis. 2020 May 6;ciaa458. doi: 10.1093/cid/ciaa458. 7) Satlin MJ, et al. Clin Infect Dis. 2020 Feb 13;ciaa121. doi: 10.1093/cid/ciaa121. 8) Pogue JM, et al. Antimicrob Agents Chemother. 2020 Jan 27;64(2):e01495-19. doi: 10.1128/AAC.01495-19. 9) Ambrose PG, et al. Open Forum Infect Dis. 2020 Mar 13;7(7):ofaa084. doi: 10.1093/ofid/ofaa084. 10) Singh N, et al…

#27 – Expert Updates in Gram Negative Resistance: Q&A Session

This is part 2 of a continuing education series produced in partnership with the SIDP Education Center (SIDPEC) on gram-negative bacterial resistance. It features expert speakers, Drs. Keith Kaye (@Keith_S_Kaye) and Kimberly Claeys (@ClaeysKcclaeys) and host Julie Ann Justo (@julie_justo). If you missed part 1 of this series, delivered as a webinar lecture, please go to sidp.org/SIDPEC to view that portion of the series first. In this podcast, our experts answer a collation of > 150 questions from interested viewers on the nuances of gram-negative bacterial resistance, from real-world formulary considerations to microbiology lab implementation and more. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#26 – OPAT - The Final Frontier, Part 2

Gain insight into Outpatient Parenteral Antibiotic Therapy (OPAT) practices across the country from Drs. Jessie Ortwine (@jkortwine), Monica Mahoney (@mmpharmd), Keenan Ryan (@keenanconazole), Monica Donnelley (@DonnelleyMonica), and Meera Mehta. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#25 – Remdesivir: Ethical and Practical Considerations for Allocation, Tracking, and More

Drs. Julie Ann Justo (@julie_justo), Erin McCreary (@erinmccreary), and Helen Newland (@helennewland) discuss ethical allocation of Emergency Use Authorization remdesivir for patients with COVID-19. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#24 – OPAT – The Final Frontier, Part 1

Gain insight into Outpatient Parenteral Antibiotic Therapy (OPAT) practices across the country from Drs. Jessie Ortwine (@jkortwine), Monica Mahoney (@mmpharmd), Keenan Ryan (@keenanconazole), Monica Donnelley (@DonnelleyMonica), and Meera Mehta. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#23 – Taking a “BITE” Out of Antibiotic Prescribing: Strategies to Improve Antimicrobial Usage in Dentistry

Dr. Katie Suda (@sudamonas) and Dr. Erinne Kennedy join Dr. Zahra Escobar (@zkepharmd) of the Breakpoints team to discuss strategies to improve antibiotic utilization and forge connections with our dental colleagues to achieve a common goal of improved patient outcomes. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#22 – Taking a “BITE” Out of Antibiotic Prescribing: The Need for Antimicrobial Stewardship in Dentistry

Dr. Katie Suda (@sudamonas) and Dr. Erinne Kennedy join Dr. Zahra Escobar (@zkepharmd) of the Breakpoints team to discuss why dentists prescribe 1 in 10 of all antibiotics in the United States and how COVID-19 risks are being managed among dentists and other oral health providers. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#21 – Frontline Allies: Emergency Medicine and Critical Care Insights into COVID19

Dr. Jenny Koehl (@jlkoehl), Dr. Karen Berger (@karenccrx), and Dr. Karen Dohr join host Erin McCreary (@erinmccreary) to discuss taking care of patients with COVID-19 in the Emergency Department and Intensive Care Unit. Listen as the team reflects on their first patients, PPE, anticoagulation, corticosteroid controversies, and more! Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#20 – What is Happening Right Now? COVID-19 Challenges and Silver Linings

Julie Ann Justo (@julie_justo), Jason Pogue (@jpogue1), and Erin McCreary (@erinmccreary) discuss critically evaluating COVID-19 literature, staying calm in the storm, strategies for team education and communication, and the role of social media in a pandemic. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#19 – Push and Pull: Combating Antibiotic Resistance from Discovery to Market Reform

Dr. Mike Dudley (@MikeMndudley), President and CEO of Qpex Biopharma, joins Dr. Erin McCreary (@erinmccreary) to discuss the thrills and failures of antibiotic discovery and development along with the critical need for antibiotic market reform. We discuss the complexity of antibiotic resistance in gram-negative pathogens, antibiotic targets, potential market solutions, and more! Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#18 – Waking the Sleeping Giant: Engaging Nurses in Antimicrobial Stewardship

Dr. David Ha (@DHpharmd) interviews Dr. Rita Olans (@RitaOlans) and Dr. Elizabeth Monsees (@eamonsees) about the critical role nurses play in antimicrobial stewardship. They discuss how nursing practice overlaps with stewardship teams, case examples of nurse integration in stewardship in various practice settings, guidance documents, and real-world advice for advancing your stewardship services with nursing collaboration. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#17 – See C. diff: A Discussion on Patient Advocacy

Christian John Lillis, co-founder and Executive Director of the Peggy Lillis Foundation (@peggyfund), joins Erin McCreary (@erinmccreary) to share his mother’s story and discuss opportunities and challenges for patient advocacy and antimicrobial resistance. Get involved with the Peggy Lillis Foundation: https://peggyfoundation.org/get-involved/take-action/ Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#16 – 5 Ways Hospital Pharmacists Can Be Antibiotics Aware

Dr. Susan Davis (@IDPharmProf) and Dr. Jason Pogue (@jpogue1) celebrate Antibiotic Awareness Week by discussing the 5 Ways Hospital Pharmacists Can Be Antibiotics Aware, including: verify penicillin allergy, avoid duplicate anaerobic coverage, reassess antibiotic therapy, avoid treatment of asymptomatic bacteriuria, use the shortest effective antibiotic duration. CDC Poster: https://www.cdc.gov/antibiotic-use/community/pdfs/Hospital-Pharmacist-Poster-508.pdf Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#15 – CDC Core Elements of Hospital Antibiotic Stewardship Programs: 2019 Update

Dr. Arjun Srinivasan and Dr. Melinda Neuhauser join host Dr. Erin McCreary (@erinmccreary) to discuss the updated Core Elements of Hospital Antibiotic Stewardship Programs from the Centers for Disease Control and Prevention. These updates emphasize the importance of pharmacist and physician co-led stewardship programs and expanding the stewardship team to all hospital groups and departments. CDC Core Elements 2019: https://www.cdc.gov/antibiotic-use/healthcare/pdfs/hospital-core-elements-H.pdf Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#14 – Pumpkin-Spiced Lessons: Phages, Posters, and Paul Sax

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) are joined by Dr. Paul Sax (@PaulSaxMD) to review important updates in HIV care from IDWeek 2019. They also go “rapid fire” through posters and oral abstracts presented at IDWeek 2019, nerd out over genomics, phages, and beta-lactamases, and discuss the new CAP and vancomycin guidelines. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#13 – Provocative Titles and Pro-Con Debates

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) discuss the IDWeek 2019 session "We're Part of the Problem: How ID Killed Antibiotic Development' and other hot topics including pro-con debates, behavioral approaches to antimicrobial stewardship, and more. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#12 – Late Breaker Trials and #WhyIVaccinate

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) share some big announcements from IDWeek 2019 including the #WhyIVaccinate movement, data from late-breaking clinical trials, new partnerships, and more! Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#11 – Practice-changing Publications ft. David van Duin

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) are joined by Dr. David van Duin (@davidvanduin) to review “Clinical Trials That Might Change Your Practice” in bacteriology, virology, and mycology from IDWeek 2019. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#10 – So You're an Antimicrobial Steward... Now What?

Host Erin McCreary (@erinmccreary) and expert panelists Libby Dodds Ashley (@The_Real_LDA), Lisa Dumkow (@LisaIDpharmD), and Jamie Kisgen (@KisgenUF) share real-world experiences in order to empower new (and existing) practitioners as antimicrobial stewardship leaders. Find out how to get started based on different training and work environments, develop relationships with key players, and address the importance of “big picture” goal setting within stewardship programs. Listen and learn (and get ready for some great stories!) Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#9 – Show Me the Data!

Host Erin McCreary (@erinmccreary) and expert panelists Libby Dodds Ashley (@The_Real_LDA), Lisa Dumkow (@LisaIDpharmD), and Jamie Kisgen (@KisgenUF) discuss how to market your stewardship program, with an emphasis on generating meaningful data to sustain and expand your program. Panelists share how they balance day-to-day activities with moving big projects forward, leveraging learners, presenting to the C-suite, and more. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#8 – Stewardship is a Team Sport

Journey with host Erin McCreary (@erinmccreary) and expert panelists Libby Dodds Ashley (@The_Real_LDA), Lisa Dumkow (@LisaIDpharmD), and Jamie Kisgen (@KisgenUF) through their lessons learned and favorite moments of their stewardship careers. We describe how to evolve as a stewardship team member and leader, enhance collaborations, promote culture change, and give and receive feedback. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#7 – Rapid Fire Data from ECCMID 2019

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) go “rapid fire” through posters and oral abstracts presented at ECCMID 2019, including: rapid diagnostics, the influence of leadership in antimicrobial stewardship, iPad technology and patient’s beliefs about antibiotics, imipenem-relebactam, cefiderocol, rezafungin, ibrexafungerp, sulbactam-ETX2514, iclaprim, lefamulin, and tebipenem. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#6 – Tazobactam and Tulips: Hot Topics from ECCMID 2019

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) review expanded MERINO trial data including mortality by pathogen MIC, PK-PD principles, BLING III, beta-lactam therapeutic drug monitoring, linezolid dosing in renal impairment, microbiology issues, and updates from EUCAST. CORRECTION: Piperacillin-tazobactam was dosed 4.5g IV every 6 hours in the Merino trial. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#5 – Nerding Out at ECCMID 2019

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) share their secret passions and nerdiest moments from ECCMID 2019, including multi-omics data for Pseudomonas aeruginosa, the effects of chemotherapy on antimicrobial resistance, phage therapy, and more! Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#4 – How ECCMID 2019 went viral

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) review results of ASPECT-NP (Ceftolozane-tazobactam versus meropenem in patients with ventilated nosocomial pneumonia), CAMERA-2 (Combination therapy for methicillin-resistant Staphylococcus aureus bacteraemia), and Exebacase for patients with methicillin-resistant Staphylococcus aureus bacteraemia (Phase 2). Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#3 – Lessons Learned From the Front Line

In the final part of our three part series on penicillin allergies host Jason Pogue (@jpogue1) and our expert panelists Julie Ann Justo (@julie_justo), Bruce Jones (@Bruce_M_Jones), and Mary Staicu (@marylynnstaicu) discuss important clinical pearls and lessons learned from the front line that can be helpful for those interested in starting a penicillin allergy program. The panel then wraps up by discussing future directions for penicillin allergy management. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ This podcast is powered by Pinecast.

#2 – Implementing Penicillin Skin Testing

In episode 2 host Jason Pogue (@jpogue1) and panelists Julie Ann Justo (@julie_justo), Bruce Jones (@Bruce_M_Jones), and Mary Staicu (@marylynnstaicu) discuss strategies for allergy reconciliation and implementation of penicillin skin testing. They discuss their experience with different penicillin skin testing models and how their institution landed on those models. They also describe what factors should be taken into consideration in order to determine which model works best for your institution, and what resources are available to get you started. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ This podcast is powered by Pinecast.

#1 – Mythbusting

In this episode host Jason Pogue (@jpogue1) discusses common misconceptions surrounding penicillin allergies, provides evidence to dispute these misgivings, and describes some of the consequences that arise from an inappropriate penicillin allergy label for a patient with expert panelists Julie Ann Justo (@julie_justo), Bruce Jones (@Bruce_M_Jones), and Mary Staicu (@marylynnstaicu). Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ This podcast is powered by Pinecast.

Search

Clear search

Close search

Google apps

Main menu